MedTrace Logo

Detection and Characterization of Anti-SARS-CoV-2 Salivary Antibodies After COVID-19 Booster Vaccines

NCT05142540 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 140

Last updated 2023-01-11

No results posted yet for this study

Summary

The investigators aim to evaluate the ability of a COVID-19 (Coronavirus disease) booster vaccine to induce a salivary antibody response and investigate a possible correlation with the serum antibody response and the cellular response.

The investigators will conduct a prospective single center cohort study including fully vaccinated probands.

Conditions

  • Anti-SARS-CoV-2 Antibody Response

Interventions

PROCEDURE

blood and saliva samples will be taken

For serology, 8 ml of blood and 1.5 ml saliva samples will be taken at every visit. For testing cellular immunity, additional 24 ml of blood will be drawn at visits 1 and 2.

Sponsors & Collaborators

  • Medical University of Graz

    lead OTHER

Principal Investigators

  • Martin Stradner · Medical University Graz Austria

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-01
Primary Completion
2022-10-04
Completion
2022-10-04

Countries

  • Austria

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05142540 on ClinicalTrials.gov